Share

3rd Annual Brain Metastases Research and Emerging Therapy Conference

We are pleased to welcome you to Marseille for the third Annual Brain Metastases Research and Emerging Therapy Conference. Last year’s successful edition has prompted us to once again organize this conference. Over the past several months, the EORTC has launched the development of a Brain Metastasis platform, created in August 2012, in order to optimally develop and conduct projects focusing on brain metastases.

This research platform brings together the multidisciplinary approach that is needed to develop brain metastases projects across several tumor types and disciplines such as breast cancer, lung cancer, melanoma, imaging, pathobiology and radiation oncology. It is expected that this cross-sectional platform stimulates innovative and insightful research in a collaborative environment in order to improve the standard of care and methodology of clinical research.

Together, the EORTC, GRPCMac and Canceropole PACA have decided to jointly organize the “Annual Brain Metastases Research and Emerging Therapy Conference” which will be held under the auspices of the EORTC. The organizing committee hopes that this meeting will provide an exceptional opportunity for you to share your collective expertise ranging from basic science to new treatments in order to facilitate ongoing studies and lay the foundation for future collaborative projects.

On behalf of the Organizing Committee.

Back to news list

Related News

  • EORTC Quality of Life Group celebrating 40 years

  • Results of two EORTC studies have been published in NEJM and the Lancet Oncology

  • Interview with Winette van der Graaf: enhanced patient participation in trials may help make cancer research more heterogeneous

  • New results, updates, and forthcoming EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer presented at ESMO 2022

  • Important new data from EORTC trials to be presented at ESMO 2022

  • EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds

  • EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma

  • In Memoriam: Dr Martin Charles Mihm

  • The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)

  • PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation